FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $213,433 | -55.4% | 100,676 | +0.1% | 0.00% | – |
| Q2 2023 | $478,547 | -14.6% | 100,535 | +2.3% | 0.00% | – |
| Q1 2023 | $560,270 | -43.8% | 98,293 | -1.1% | 0.00% | -100.0% |
| Q4 2022 | $996,885 | -54.9% | 99,386 | +0.5% | 0.00% | -50.0% |
| Q3 2022 | $2,211,722 | -3.6% | 98,899 | +7.1% | 0.00% | 0.0% |
| Q2 2022 | $2,293,368 | -36.9% | 92,314 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $3,635,744 | +48.8% | 92,139 | +123.9% | 0.00% | +100.0% |
| Q4 2021 | $2,444,000 | -0.6% | 41,145 | -0.8% | 0.00% | -50.0% |
| Q3 2021 | $2,459,000 | -37.0% | 41,496 | -7.7% | 0.00% | -33.3% |
| Q2 2021 | $3,904,000 | +10.9% | 44,979 | +5.3% | 0.00% | 0.0% |
| Q1 2021 | $3,521,000 | -9.6% | 42,700 | -0.3% | 0.00% | -25.0% |
| Q4 2020 | $3,895,000 | +138.1% | 42,830 | +4.7% | 0.00% | +100.0% |
| Q3 2020 | $1,636,000 | +33.8% | 40,923 | +9.1% | 0.00% | +100.0% |
| Q2 2020 | $1,223,000 | +41.6% | 37,519 | -3.6% | 0.00% | 0.0% |
| Q1 2020 | $864,000 | +37.8% | 38,908 | +21.5% | 0.00% | 0.0% |
| Q4 2019 | $627,000 | +22.5% | 32,016 | -3.3% | 0.00% | 0.0% |
| Q3 2019 | $512,000 | -23.9% | 33,117 | -0.0% | 0.00% | 0.0% |
| Q2 2019 | $673,000 | -4.0% | 33,129 | -17.0% | 0.00% | 0.0% |
| Q1 2019 | $701,000 | +56.1% | 39,929 | +14.2% | 0.00% | 0.0% |
| Q4 2018 | $449,000 | -19.0% | 34,962 | +2.8% | 0.00% | 0.0% |
| Q3 2018 | $554,000 | +28.2% | 34,019 | -10.8% | 0.00% | – |
| Q2 2018 | $432,000 | +20.0% | 38,120 | +3.1% | 0.00% | – |
| Q1 2018 | $360,000 | +77.3% | 36,977 | +10.9% | 0.00% | – |
| Q4 2017 | $203,000 | +147.6% | 33,337 | +61.4% | 0.00% | – |
| Q3 2017 | $82,000 | +8100.0% | 20,651 | +9244.3% | 0.00% | – |
| Q2 2017 | $1,000 | 0.0% | 221 | +20.1% | 0.00% | – |
| Q1 2017 | $1,000 | – | 184 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 184 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | – | 184 | 0.0% | 0.00% | – |
| Q2 2016 | $0 | – | 184 | 0.0% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 184 | 0.0% | 0.00% | – |
| Q4 2015 | $1,000 | 0.0% | 184 | 0.0% | 0.00% | – |
| Q3 2015 | $1,000 | 0.0% | 184 | 0.0% | 0.00% | – |
| Q2 2015 | $1,000 | – | 184 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |